目的通过比较常规治疗与加用尤瑞克林治疗急性脑梗死的临床疗效比较及治疗前后NIHSS神经功能缺损评分比较,论证尤瑞克林在急性轻中度脑梗死治疗中的应用价值。方法 96例急性轻中度脑梗死患者随机分为对照组(常规治疗)与实验组(常规治疗加尤瑞克林),比较两组患者治疗效果,并作统计分析。用t检验比较两组患者治疗前后的NIHSS评分,作差异显著性分析。结果尤瑞克林组病情改善比率明显高于对照组,差异具有统计学意义(P<0.05);病情无变化比率低于对照组(P<0.05);病情恶化或死亡比率在两组间无显著性差异(P>0.05)。治疗后尤瑞克林组NIHSS神经功能缺损评分明显低于对照组(P<0.01)。结论巴曲酶对于急性脑梗死,尤其是轻中度患者,具有良好的治疗效果,安全有效,值得推广应用。 OBJECTIVE: To compare the clinical efficacy of conventional therapy with Urethrin in the treatment of acute cerebral infarction and to compare NIHSS neurological deficit scores before and after treatment to demonstrate the clinical value of uricclin in the treatment of acute mild-moderate cerebral infarction. Methods Ninety-six patients with acute mild-to-moderate cerebral infarction were randomly divided into control group (conventional treatment) and experimental group (conventional treatment plus canavirin). The therapeutic effect was compared between the two groups and statistically analyzed. The NIHSS scores of two groups before and after treatment were compared by t-test for significant difference analysis. Results The rate of improvement was significantly higher in the uricin group than in the control group (P <0.05). The rate of change in the disease was lower than that in the control group (P <0.05). The rate of progression or death was no significant difference between the two groups Significant difference (P> 0.05). NIHSS neurological deficit score in the uric-nin-kills group was significantly lower than that in the control group after treatment (P <0.01). Conclusion Batroxobin has a good therapeutic effect on acute cerebral infarction, especially in patients with mild to moderate disease, which is safe and effective and should be widely applied.